Dondi Rust, BS

Moderna
Cambridge, Massachusetts, United States

Disclosure information not submitted.

Presentation(s):

• 220 - Safety and Immunogenicity of mRNA-1018, a candidate vaccine for the prevention of H5N1 pandemic influenza, in healthy adults ≥18 years of age in a dose-ranging Phase 1/2 clinical study

  Monday, October 20, 2025
  3:39 PM - 3:51 PM US ET